Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched studyOriginal Research Published on 2024-03-262024-09-05 Journal: Therapeutic Advances in Infectious Disease [Category] update2024, [키워드] COVID-19 early treatment Nirmatrelvir/ritonavir Remdesivir [DOI] 10.1177/20499361241236582 PMC 바로가기 [Article Type] Original Research
Early treatment with fluvoxamine, bromhexine, cyproheptadine, and niclosamide to prevent clinical deterioration in patients with symptomatic COVID-19: a randomized clinical trialArticle Published on 2024-03-142024-09-05 Journal: EClinicalMedicine [Category] update2024, [키워드] bromhexine COVID-19 treatment Cyproheptadine early treatment fluvoxamine niclosamide [DOI] 10.1016/j.eclinm.2024.102517 PMC 바로가기 [Article Type] Article
Utilizing the sublingual form of squalene in COVID-19 patients: a randomized clinical trialArticle Published on 2024-02-242024-09-05 Journal: Scientific Reports [Category] update2024, [키워드] COVID-19 Diseases early treatment immunology Medical research mortality rate Re-hospitalization SARS-CoV-2 squalene [DOI] 10.1038/s41598-024-54843-x PMC 바로가기 [Article Type] Article
Efficacy of sotrovimab on omicron BA.2, BA.4 and BA.5 subvariants of sars-cov-2 vs. other early therapies: a systematic review and meta-analysis of literature dataImmunology Systematic Review Published on 2024-01-302024-09-05 Journal: Frontiers in immunology [Category] update2024, [키워드] COVID-19 early treatment Hospitalization monoclonal antibodies Mortality [DOI] 10.3389/fimmu.2024.1295029 PMC 바로가기 [Article Type] Immunology Systematic Review
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trialResearch Published on 2024-01-152024-09-05 Journal: BMC Infectious Diseases [Category] update2024, [키워드] antiviral efficacy COVID-19 early treatment Favipiravir Pharmacometrics SARS-CoV-2 [DOI] 10.1186/s12879-023-08835-3 PMC 바로가기 [Article Type] Research
COVID-19 pharmaceuticals in aquatic matrices: The threatening effects over cyanobacteria and microalgaeArticle Published on 2023-05-242024-09-05 Journal: The Science of the total environment [Category] update2024, [키워드] coronavirus early treatment ecotoxicology water contamination [DOI] 10.1016/j.scitotenv.2023.164309 PMC 바로가기 [Article Type] Article
Early treatment of Favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control studyArticle Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] 95% CI adjusted hazard ratio Antiviral ARMS clinical clinical condition Clinical improvement complications control arm COVID-19 COVID-19 patient Day defined early treatment Effect Efficacy enrolled enrolment faster Favipiravir female FPV investigated likelihood median median time mild case mild pneumonia multicentre Patient PCR-confirmed Pneumonia primary endpoint randomized control study RdRP RdRp inhibitor registry risk of COVID-19 SARS-CoV-2-infected patient score significantly higher supportive care sustained symptomatic Thailand Treatment viral clearance Viral detection [DOI] 10.1080/22221751.2022.2117092 PMC 바로가기
Using time-weighted average change from baseline of SARS-CoV-2 viral load to assess impact of hydroxychloroquine as postexposure prophylaxis and early treatment for COVID-19Meta-Analysis Published on 2022-12-012023-07-10 Journal: Journal of medical virology [Category] COVID19(2023년), [키워드] COVID-19 early treatment Hydroxychloroquine PEP SARS-CoV-2 [DOI] 10.1002/jmv.28054 PMC 바로가기 [Article Type] Meta-Analysis
Early 3-day course of remdesivir to prevent progression to severe Covid-19 in high-risk patients with hospital-acquired SARS-CoV-2 infection: preliminary results from two Italian outbreaksArticle Published on 2022-12-012023-07-11 Journal: New Microbiologica [Category] COVID19(2023년), [키워드] COVID-19 early treatment Nosocomial infection Remdesivir SARS-CoV-2
Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective studyArticle Published on 2022-10-202022-11-15 Journal: BMC Infectious Diseases [Category] COVID19(2023년), SARS, 변종, 진단, 치료제, [키워드] adverse events Algorithm antibody Antiviral antiviral drug antivirals approved benefit Calabria case sery clinical clinical evolution Combination combination therapy combined use coronavirus disease COVID-19 COVID-19 progression drug Early therapies early treatment effective Effectiveness Efficacy escape mutant group Health services hospital Hospital admission hospitalisation Hospitalized hypothesised Immunocompromised immunocompromised individuals implication increase in lesson mAb mAbs malignancy monoclonal antibodies monoclonal antibody monotherapy Patient patients patients treated progression provided receive reduce reported Retrospective study SARS-CoV-2 SARS-CoV-2 genome Support symptom onset Territorial health services. Therapies therapy treated treated patient Treatment [DOI] 10.1186/s12879-022-07774-9 PMC 바로가기